

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Granules India's revenue surges by 21% to Rs 468 Cr.

24 July 2018 | News

The Company reported a standalone Total Income during the quarter of INR 458 Crs. EBITDA for the quarter was INR 88 Crs. and PAT stood at INR 40 Cr. respectively



Granules India Ltd., a growing pharmaceutical manufacturing company, announced its financial results for the first quarter ended 30th June 2018.

The Company reported a standalone Total Income during the quarter of INR 458 Crs. EBITDA for the quarter was INR 88 Crs. and PAT stood at INR 40 Cr. respectively.

The Company's Board of Directors has proposed a final dividend of 25 paise / share of face value of Rs. 1 each.

Commenting on the development, Granules India Chairman & MD Krishna Prasad Chigurupati said: "The first quarter of the current financial year started on a positive note, we saw our total income increase by 21 percent compared to the same period of previous fiscal."

There was also a sequential growth in margin profiles despite the continuing raw material pricing pressures, he added.

The company said its board has declared first interim dividend of 25 paise per share of face value of Re 1 each and has also approved further investment of up to USD 15 million by way of debt/equity in company's wholly owned arm Granules Pharmaceutical Inc.